Clearance of xenon-133 from bone marrow in patients with small-cell lung cancer.
The aim of this study was to estimate bone-marrow blood flow (BMBF) in man and to correlate this with myelosuppression induced by cytostatic treatment dosed as a function of surface area. Twenty-four patients suffering from small-cell lung cancer participated in the study. Blood flow was measured with the xenon-133 washout technique. The 133Xe clearance measurement took place in conjunction with the pre-treatment bone-marrow staging procedure (ad modern Radner). Tissue samples were taken for microscopy and for the determination of the blood-to-tissue partition coefficient lambda. After the bone-marrow aspiration, 0.1-0.2 ml of 133Xe in saline was injected into the bone marrow and the cannula was removed. Following a hyperaemic phase of 12 min (7-16 min), monoexponential washouts were demonstrated. The median washout rate constant was 0.0063 min-1 (0.0038-0.0098 min-1). Lambda values of 0.3-3.5 ml g were found, but microscopy of the bone marrow showed a fairly large admixture of peripheral blood. Therefore, the lambda values should be taken with caution and absolute blood-flow values were not calculated. The results demonstrated no correlation between 133Xe clearance from crista iliaca and leucocyte or platelet suppression.
Petersen
L J
LJ
Department of Clinical Physiology and Nuclear Medicine, Bispebjerg Hospital, Denmark.
Friberg
L
L
Jensen
J
J
Bülow
J
J
Hansen
M
M
Madsen
J
J
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001853:Bone Marrow / Q000098:blood supply / Q000378:metabolism*; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects; D012039:Regional Blood Flow / Q000502:physiology / Q000528:radiation effects*; D012044:Regression Analysis; D014980:Xenon Radioisotopes / Q000493:pharmacokinetics*
D000970:Antineoplastic Agents; D014980:Xenon Radioisotopes